Staar Surgical's ICL
This article was originally published in The Gray Sheet
Executive Summary
Start of Phase II trials of the implantable contact lens for hyperopia (farsightedness) is announced by the company March 25. FDA's approval allows the company to expand its investigator base from four to 10 surgeons and to implant 62 ICLs in patients. A Phase I hyperopia trial conducted outside the U.S. included 10 patients with an average preoperative hyperopia of 6.05 diopters. Results showed seven of the ten patients with 20/20 vision or better without glasses or contact lenses and all 10 had 20/40 or better following the procedure, the company claims. Placed in the eye during a suture-less outpatient procedure, the ICL is currently in Phase II trials for myopia. The company hopes to commence Phase III of that trial in the near future. The company received CE mark approval for the ICL in July
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: